Literature DB >> 35034193

A broad clinical spectrum of PLCε1-related kidney disease and intrafamilial variability.

Esra Karabağ Yılmaz1, Seha Saygili1, Bora Gulhan2, Nur Canpolat1, Aysun Karabay Bayazıt3, Beltinge Demircioglu Kilic4, Nurver Akıncı5, Meryem Benzer6, Nilufer Goknar7, Asli Kavaz Tufan8, Mukaddes Kalyoncu9, Hulya Nalcacioglu10, Demet Tekcan10, Gizem Yıldız11, Ayse Agbas1, Ahmet Nayır12, Rezan Topaloglu2, Salim Caliskan1, Fatih Ozaltin13,14.   

Abstract

BACKGROUND: The phenotypic and genotypic spectrum and kidney outcome of PLCε1-related kidney disease are not well known. We attempted to study 25 genetically confirmed cases of PLCε1-related kidney disease from 11 centers to expand the clinical spectrum and to determine the relationship between phenotypic and genotypic features, kidney outcome, and the impact of treatment on outcome.
METHODS: Data regarding demographics, clinical and laboratory characteristics, histopathological and genetic test results, and treatments were evaluated retrospectively.
RESULTS: Of 25 patients, 36% presented with isolated proteinuria, 28% with nephrotic syndrome, and 36% with chronic kidney disease stage 5. Twenty patients underwent kidney biopsy, 13 (65%) showed focal segmental glomerulosclerosis (FSGS), and 7 (35%) showed diffuse mesangial sclerosis (DMS). Of the mutations identified, 80% had non-missense, and 20% had missense; ten were novel. No clear genotype-phenotype correlation was observed; however, significant intrafamilial variations were observed in three families. Patients with isolated proteinuria had significantly better kidney survival than patients with nephrotic syndrome at onset (p = 0.0004). Patients with FSGS had significantly better kidney survival than patients with DMS (p = 0.007). Patients who presented with nephrotic syndrome did not respond to any immunosuppressive therapy; however, 4/9 children who presented with isolated proteinuria showed a decrease in proteinuria with steroids and/or calcineurin inhibitors.
CONCLUSION: PLCε1-related kidney disease may occur in a wide clinical spectrum, and genetic variations are not associated with clinical presentation or disease course. However, clinical presentation and histopathology appear to be important determinants for prognosis. Immunosuppressive medications in addition to angiotensin-converting enzyme inhibitors may be beneficial for selected patients. "A higher resolution version of the Graphical abstract is available as Supplementary information".
© 2021. The Author(s), under exclusive licence to International Pediatric Nephrology Association.

Entities:  

Keywords:  Children; Diffuse mesangial sclerosis; Focal segmental glomerulosclerosis; Intrafamilial variability; PLCε1; Prognosis; Treatment

Mesh:

Substances:

Year:  2022        PMID: 35034193     DOI: 10.1007/s00467-021-05371-7

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.651


  20 in total

1.  Familial focal segmental glomerulosclerosis with PLCE1 mutation in siblings.

Authors:  Masaki Shimizu; Hitoshi Irabu; Hisashi Kaneda; Kazuhide Ohta; Kandai Nozu
Journal:  Pediatr Int       Date:  2019-07       Impact factor: 1.524

2.  Mutational analysis of the PLCE1 gene in steroid resistant nephrotic syndrome.

Authors:  Olivia Boyer; Geneviève Benoit; Olivier Gribouval; Fabien Nevo; Audrey Pawtowski; Ilmay Bilge; Zelal Bircan; Georges Deschênes; Lisa M Guay-Woodford; Michelle Hall; Marie-Alice Macher; Kenza Soulami; Constantinos J Stefanidis; Robert Weiss; Chantal Loirat; Marie-Claire Gubler; Corinne Antignac
Journal:  J Med Genet       Date:  2010-07       Impact factor: 6.318

3.  Whole Exome Sequencing of Patients with Steroid-Resistant Nephrotic Syndrome.

Authors:  Jillian K Warejko; Weizhen Tan; Ankana Daga; David Schapiro; Jennifer A Lawson; Shirlee Shril; Svjetlana Lovric; Shazia Ashraf; Jia Rao; Tobias Hermle; Tilman Jobst-Schwan; Eugen Widmeier; Amar J Majmundar; Ronen Schneider; Heon Yung Gee; J Magdalena Schmidt; Asaf Vivante; Amelie T van der Ven; Hadas Ityel; Jing Chen; Carolin E Sadowski; Stefan Kohl; Werner L Pabst; Makiko Nakayama; Michael J G Somers; Nancy M Rodig; Ghaleb Daouk; Michelle Baum; Deborah R Stein; Michael A Ferguson; Avram Z Traum; Neveen A Soliman; Jameela A Kari; Sherif El Desoky; Hanan Fathy; Martin Zenker; Sevcan A Bakkaloglu; Dominik Müller; Aytul Noyan; Fatih Ozaltin; Melissa A Cadnapaphornchai; Seema Hashmi; Jeffrey Hopcian; Jeffrey B Kopp; Nadine Benador; Detlef Bockenhauer; Radovan Bogdanovic; Nataša Stajić; Gil Chernin; Robert Ettenger; Henry Fehrenbach; Markus Kemper; Reyner Loza Munarriz; Ludmila Podracka; Rainer Büscher; Erkin Serdaroglu; Velibor Tasic; Shrikant Mane; Richard P Lifton; Daniela A Braun; Friedhelm Hildebrandt
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-10       Impact factor: 8.237

Review 4.  Idiopathic nephrotic syndrome in children.

Authors:  Damien G Noone; Kazumoto Iijima; Rulan Parekh
Journal:  Lancet       Date:  2018-06-14       Impact factor: 79.321

5.  Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible.

Authors:  Bernward Hinkes; Roger C Wiggins; Rasheed Gbadegesin; Christopher N Vlangos; Dominik Seelow; Gudrun Nürnberg; Puneet Garg; Rakesh Verma; Hassan Chaib; Bethan E Hoskins; Shazia Ashraf; Christian Becker; Hans Christian Hennies; Meera Goyal; Bryan L Wharram; Asher D Schachter; Sudha Mudumana; Iain Drummond; Dontscho Kerjaschki; Rüdiger Waldherr; Alexander Dietrich; Fatih Ozaltin; Aysin Bakkaloglu; Roxana Cleper; Lina Basel-Vanagaite; Martin Pohl; Martin Griebel; Alexey N Tsygin; Alper Soylu; Dominik Müller; Caroline S Sorli; Tom D Bunney; Matilda Katan; Jinhong Liu; Massimo Attanasio; John F O'toole; Katrin Hasselbacher; Bettina Mucha; Edgar A Otto; Rannar Airik; Andreas Kispert; Grant G Kelley; Alan V Smrcka; Thomas Gudermann; Lawrence B Holzman; Peter Nürnberg; Friedhelm Hildebrandt
Journal:  Nat Genet       Date:  2006-11-05       Impact factor: 38.330

6.  Mutations in PLCE1 are a major cause of isolated diffuse mesangial sclerosis (IDMS).

Authors:  Rasheed Gbadegesin; Bernward G Hinkes; Bethan E Hoskins; Christopher N Vlangos; Saskia F Heeringa; Jinhong Liu; Chantal Loirat; Fatih Ozaltin; Seema Hashmi; Francis Ulmer; Roxanna Cleper; Robert Ettenger; Corinne Antignac; Roger C Wiggins; Martin Zenker; Friedhelm Hildebrandt
Journal:  Nephrol Dial Transplant       Date:  2007-12-08       Impact factor: 5.992

7.  Exclusion of homozygous PLCE1 (NPHS3) mutations in 69 families with idiopathic and hereditary FSGS.

Authors:  Rasheed Gbadegesin; Bartlomiej Bartkowiak; Peter J Lavin; Nirvan Mukerji; Guanghong Wu; Brandy Bowling; Jason Eckel; Tirupapuliyur Damodaran; Michelle P Winn
Journal:  Pediatr Nephrol       Date:  2008-10-31       Impact factor: 3.714

8.  A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome.

Authors:  Carolin E Sadowski; Svjetlana Lovric; Shazia Ashraf; Werner L Pabst; Heon Yung Gee; Stefan Kohl; Susanne Engelmann; Virginia Vega-Warner; Humphrey Fang; Jan Halbritter; Michael J Somers; Weizhen Tan; Shirlee Shril; Inès Fessi; Richard P Lifton; Detlef Bockenhauer; Sherif El-Desoky; Jameela A Kari; Martin Zenker; Markus J Kemper; Dominik Mueller; Hanan M Fathy; Neveen A Soliman; Friedhelm Hildebrandt
Journal:  J Am Soc Nephrol       Date:  2014-10-27       Impact factor: 10.121

Review 9.  IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome.

Authors:  Agnes Trautmann; Marina Vivarelli; Susan Samuel; Debbie Gipson; Aditi Sinha; Franz Schaefer; Ng Kar Hui; Olivia Boyer; Moin A Saleem; Luciana Feltran; Janina Müller-Deile; Jan Ulrich Becker; Francisco Cano; Hong Xu; Yam Ngo Lim; William Smoyer; Ifeoma Anochie; Koichi Nakanishi; Elisabeth Hodson; Dieter Haffner
Journal:  Pediatr Nephrol       Date:  2020-05-07       Impact factor: 3.714

10.  PLCE1 regulates the migration, proliferation, and differentiation of podocytes.

Authors:  Seyoung Yu; Won-Il Choi; Yo Jun Choi; Hye-Youn Kim; Friedhelm Hildebrandt; Heon Yung Gee
Journal:  Exp Mol Med       Date:  2020-04-01       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.